AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson’s disease

Click here to view online. Add this email to your safelist.

29 August 2017

AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.